U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H24N2O4
Molecular Weight 344.4056
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FORMOTEROL

SMILES

C[C@]([H])(Cc1ccc(cc1)OC)NC[C@@]([H])(c2ccc(c(c2)N=CO)O)O

InChI

InChIKey=BPZSYCZIITTYBL-YJYMSZOUSA-N
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H24N2O4
Molecular Weight 344.4056
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf

Formoterol is a long-acting selective beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1- receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10%-50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2- agonists may have cardiac effects. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including formoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibits the release of pro-inflammatory mast-cell mediators such as histamine and leukotrienes. Formoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown. Formoterol is used for use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator. Not indicated for asthma that can be successfully managed with occasional use of an inhaled, short-acting beta2-adrenergic agonist. Also used for the prevention of exercise-induced bronchospasm, as well as long-term treatment of bronchospasm associated with COPD. Marketed as Foradil Aerolizer.

CNS Activity

Curator's Comment:: can partially cross the blood-brain barrier https://med.stanford.edu/news/all-news/2013/07/drug-improves-cognitive-function-in-mouse-model-of-down-syndrome-study-says.html

Originator

Curator's Comment:: Novartis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.2 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FORADIL AEROLIZER

Approved Use

FORADIL AEROLIZER is a LABA indicated for: Treatment of asthma in patients ≥5 years as an add-on to a long-term asthma control medication such as an inhaled corticosteroid. Prevention of exercise-induced bronchospasm (EIB) in patients ≥5 years. Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).

Launch Date

9.8219518E11
Primary
FORADIL AEROLIZER

Approved Use

FORADIL AEROLIZER is a LABA indicated for: Treatment of asthma in patients ≥5 years as an add-on to a long-term asthma control medication such as an inhaled corticosteroid. Prevention of exercise-induced bronchospasm (EIB) in patients ≥5 years. Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD).

Launch Date

9.8219518E11
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses.
1992 Nov
A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study.
1998 Sep
Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
2000 Aug 1
beta(2)-adrenoceptor agonist suppresses renal tumour necrosis factor and enhances interleukin-6 gene expression induced by endotoxin.
2000 Dec
Formoterol: a review of its use in chronic obstructive pulmonary disease.
2002
Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.
2002 May
Beta2-Adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis.
2006 Aug 29
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.
2007
Formoterol in the management of chronic obstructive pulmonary disease.
2008
Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
2008 Mar
Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
2008 Nov
Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
2011
Rapid nongenomic actions of inhaled corticosteroids on long-acting β(2)-agonist transport in the airway.
2011 Dec
Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study.
2011 Nov-Dec
Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged ≥16 years) with asthma: a sub-analysis of the COSMOS study.
2012 Jul 1
Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status.
2012 Jun
Potentiated interaction between ineffective doses of budesonide and formoterol to control the inhaled cadmium-induced up-regulation of metalloproteinases and acute pulmonary inflammation in rats.
2014
Patents

Patents

Sample Use Guides

For oral inhalation only. DO NOT swallow Foradil capsule. Foradil capsule should be always used with Aerolizer inhaler ONLY. Treatment of asthma in patients ≥5 years: Inhalation of one capsule every 12 hours in addition to concomitant treatment with a long-term control medication such as an inhaled corticosteroid. EIB: Inhalation of one capsule at least 15 minutes before exercise Additional doses should not be used for 12 hours. Maintenance treatment of bronchoconstriction in patients with COPD: Inhalation of one capsule every 12 hours.
Route of Administration: Other
Formoterol (0.3nM) attenuated isoprenaline-induced bronchodilatation in human precision-cut lung slices containing small airways model.
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:30:03 UTC 2021
Edited
by admin
on Sat Jun 26 15:30:03 UTC 2021
Record UNII
5ZZ84GCW8B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FORMOTEROL
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
OXIS
Brand Name English
FORMOTEROL [HSDB]
Common Name English
FORMOTEROL [MI]
Common Name English
FORMOTEROL [WHO-DD]
Common Name English
EFORMOTEROL
Common Name English
FORMOTEROL [INN]
Common Name English
FORMOTEROL [VANDF]
Common Name English
FORMAMIDE, N-(2-HYDROXY-5-(1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QR03AK08
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
NDF-RT N0000175779
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
NCI_THESAURUS C48149
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-VATC QR03AK09
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AK08
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AK09
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
NDF-RT N0000009922
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-VATC QR03AC13
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AL07
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-VATC QR03AK07
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AK11
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AC13
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-VATC QR03AK11
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AL05
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
LIVERTOX 435
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AK07
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
WHO-ATC R03AL09
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
Code System Code Type Description
FDA UNII
5ZZ84GCW8B
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
RXCUI
25255
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M5542
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1239
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
DRUG BANK
DB00983
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
IUPHAR
3465
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
ChEMBL
CHEMBL1256786
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
INN
4935
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
LACTMED
Formoterol
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
NCI_THESAURUS
C65754
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
HSDB
7287
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
CAS
73573-87-2
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
EVMPD
SUB07788MIG
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
WIKIPEDIA
FORMOTEROL
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
EPA CompTox
73573-87-2
Created by admin on Sat Jun 26 15:30:04 UTC 2021 , Edited by admin on Sat Jun 26 15:30:04 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
Measurement of cAMP production in CHO cells stably expressing comparable levels of the human
EC50
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
TARGET -> AGONIST
Measurement of cAMP production in HEK-293 cells stably expressing comparable levels of the human
EC50
TARGET -> AGONIST
Measurement of cAMP production in CHO cells stably expressing comparable levels of the human
EC50
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC INHALED ADMINISTRATION

Biological Half-life PHARMACOKINETIC